{"id":"AZN.L-20260801","symbol":"AZN.L","date":"2026-08-01","facts":{"symbol":"AZN.L","name":"AstraZeneca PLC","sector":"Healthcare","industry":"Drug Manufacturers - General","country":"United Kingdom","summary":"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.","tradeCcy":"GBp","finCcy":"USD","isPence":true,"price":12632,"priceMajor":126.32,"mcap":195906781184,"shares":1550876987,"ev":223379324928,"beta":0.225,"high52":15732,"low52":9892,"drawdown":-0.19705059750826337,"ret6m":-0.10427546791183151,"ret12m":0.1566833441993687,"trailingPE":25.264,"forwardPE":1103.8417,"priceToBook":517.6833,"dividendYield":0.0188,"revenueTTM":61366001664,"ebitda":19904000000,"grossMargin":0.8169,"opMargin":0.23459,"profitMargin":0.17021999,"roe":0.21965,"revGrowthTTM":0.064,"ocfTTM":13699999744,"fcfTTM":4905375232,"totalCash":4968000000,"totalDebt":32349999104,"netDebt":27381999104,"est":{"rev0y":63280866390,"eps0y":10.26811,"rev1y":66853157500,"eps1y":11.44367,"growth1y":0.1145,"target":15745.683,"nAnalysts":22,"rec":"buy"},"hist":{"years":["2022","2023","2024","2025"],"revenue":[44351000000,45811000000,54073000000,58739000000],"netIncome":[3288000000,5955000000,7035000000,10225000000],"fcf":[7237000000,6567000000,7275000000,8670000000],"ocf":[9808000000,10345000000,11861000000,14575000000],"opIncome":[4512000000,8722000000,10251000000,13327000000],"eps":[2.11,3.81,4.5,6.54],"equity":[37037000000,39143000000,40786000000,48667000000],"revCAGR3":0.09818214247884915,"lossYears":0},"cyclicality":0.14627394384507914,"isFinancial":false,"chartPts":[{"d":"2024-07-28","c":12605.25},{"d":"2024-08-04","c":12695.99},{"d":"2024-08-11","c":13041.88},{"d":"2024-08-18","c":13071.87},{"d":"2024-08-25","c":13269.81},{"d":"2024-09-01","c":12646.01},{"d":"2024-09-08","c":11924.24},{"d":"2024-09-15","c":11776.28},{"d":"2024-09-22","c":11650.32},{"d":"2024-09-29","c":11734.3},{"d":"2024-10-06","c":11760.29},{"d":"2024-10-13","c":11942.23},{"d":"2024-10-20","c":11602.34},{"d":"2024-10-28","c":11018.52},{"d":"2024-11-04","c":9899.88},{"d":"2024-11-11","c":9974.85},{"d":"2024-11-18","c":10470.7},{"d":"2024-11-25","c":10608.65},{"d":"2024-12-02","c":10650.64},{"d":"2024-12-09","c":10464.7},{"d":"2024-12-16","c":10252.76},{"d":"2024-12-23","c":10456.7},{"d":"2024-12-30","c":10590.66},{"d":"2025-01-06","c":10978.54},{"d":"2025-01-13","c":10934.55},{"d":"2025-01-20","c":11046.51},{"d":"2025-01-27","c":11340.42},{"d":"2025-02-03","c":11596.34},{"d":"2025-02-10","c":11704.31},{"d":"2025-02-17","c":11705.99},{"d":"2025-02-24","c":11965.94},{"d":"2025-03-03","c":12069.92},{"d":"2025-03-10","c":11991.94},{"d":"2025-03-17","c":11606},{"d":"2025-03-24","c":11414.04},{"d":"2025-03-30","c":10806.14},{"d":"2025-04-06","c":10006.28},{"d":"2025-04-13","c":10122.26},{"d":"2025-04-20","c":10398.21},{"d":"2025-04-27","c":10752.15},{"d":"2025-05-04","c":10238.24},{"d":"2025-05-11","c":10328.22},{"d":"2025-05-18","c":10434.21},{"d":"2025-05-25","c":10718.16},{"d":"2025-06-01","c":10780.15},{"d":"2025-06-08","c":10984.11},{"d":"2025-06-15","c":10390.21},{"d":"2025-06-22","c":10222.24},{"d":"2025-06-29","c":10334.22},{"d":"2025-07-06","c":10448.2},{"d":"2025-07-13","c":10292.23},{"d":"2025-07-20","c":10800.14},{"d":"2025-07-27","c":11102.09},{"d":"2025-08-03","c":10920.88},{"d":"2025-08-10","c":11590.81},{"d":"2025-08-17","c":11966.77},{"d":"2025-08-24","c":11788.79},{"d":"2025-08-31","c":12088.76},{"d":"2025-09-07","c":11792.79},{"d":"2025-09-14","c":11302.84},{"d":"2025-09-21","c":10998.87},{"d":"2025-09-28","c":12648.7},{"d":"2025-10-05","c":12780.69},{"d":"2025-10-12","c":12556.71},{"d":"2025-10-19","c":12530.71},{"d":"2025-10-27","c":12468.72},{"d":"2025-11-03","c":12898.68},{"d":"2025-11-10","c":13530.61},{"d":"2025-11-17","c":13818.58},{"d":"2025-11-24","c":13972.57},{"d":"2025-12-01","c":13590.6},{"d":"2025-12-08","c":13442.62},{"d":"2025-12-15","c":13670.6},{"d":"2025-12-22","c":13672.6},{"d":"2025-12-29","c":13590.6},{"d":"2026-01-05","c":14214.54},{"d":"2026-01-12","c":14050.56},{"d":"2026-01-19","c":13578.61},{"d":"2026-01-26","c":13598.6},{"d":"2026-02-02","c":14102.55},{"d":"2026-02-09","c":15116.45},{"d":"2026-02-16","c":15270},{"d":"2026-02-23","c":15542},{"d":"2026-03-02","c":14500},{"d":"2026-03-09","c":14380},{"d":"2026-03-16","c":13896},{"d":"2026-03-23","c":14302},{"d":"2026-03-29","c":15316},{"d":"2026-04-05","c":15230},{"d":"2026-04-12","c":15118},{"d":"2026-04-19","c":13956},{"d":"2026-04-26","c":13512},{"d":"2026-05-03","c":13360},{"d":"2026-05-10","c":13632},{"d":"2026-05-17","c":13916},{"d":"2026-05-24","c":13802},{"d":"2026-05-31","c":13858},{"d":"2026-06-07","c":13462},{"d":"2026-06-14","c":13234},{"d":"2026-06-21","c":14318},{"d":"2026-06-28","c":14456},{"d":"2026-07-05","c":12834},{"d":"2026-07-12","c":12594},{"d":"2026-07-19","c":12670},{"d":"2026-07-26","c":12720},{"d":"2026-07-31","c":12632}],"problems":[],"fetchedUtc":"2026-08-01T07:32:50.664Z","pct":{"roe":55,"opMargin":55,"fwdPE":5,"fcfYield":30,"revGrowth":30,"ret12m":55},"fcfYieldTTM":0.025039333515427233,"fxNote":"Regnskab i USD, handel i GBp — fair value omregnes."},"val":{"viable":true,"model":"dcf","fcf0":7.28,"fcf0Ccy":"USD","anchor":"median af 3 kandidater: historisk median-FCF (3 år) = 7,3 mia. USD; TTM-FCF = 4,9 mia. USD; konsensus-nettoresultat i år × 0,70 (cash-konvertering, cyklikalitetsjusteret) = 11,1 mia. USD","scenarios":{"bear":{"perShare":2346.46,"tvShare":0.5,"g1":-0.009,"gT":0.02,"wacc":0.09,"fcfMult":0.81,"prob":0.25},"base":{"perShare":6627.66,"tvShare":0.61,"g1":0.073,"gT":0.025,"wacc":0.08,"fcfMult":1,"prob":0.5},"bull":{"perShare":13406.58,"tvShare":0.7,"g1":0.138,"gT":0.03,"wacc":0.073,"fcfMult":1.1,"prob":0.25}},"probs":{"bear":0.25,"base":0.5,"bull":0.25},"weighted":7252.09,"upside":-0.426,"impliedG1":0.211,"sensitivity":{"waccLabels":["-2 pp","-1 pp","8,0 %","+1 pp","+2 pp"],"rows":[{"label":"4,4 mia. USD","cells":[6243,4537,3453,2703,2154]},{"label":"5,8 mia. USD","cells":[8760,6486,5040,4041,3308]},{"label":"7,3 mia. USD","cells":[11277,8435,6628,5378,4463]},{"label":"9,1 mia. USD","cells":[14424,10871,8612,7050,5906]},{"label":"10,9 mia. USD","cells":[17571,13307,10596,8722,7349]}]},"assumptions":["FCF-anker: 7,3 mia. USD (median af 3 kandidater: historisk median-FCF (3 år) = 7,3 mia. USD; TTM-FCF = 4,9 mia. USD; konsensus-nettoresultat i år × 0,70 (cash-konvertering, cyklikalitetsjusteret) = 11,1 mia. USD).","Krydstjek: konsensus-nettoresultat i år (15,9 mia. USD) ligger klart over FCF-ankeret — modellen anker bevidst i historisk cash flow, ikke i estimaterne. Er estimaterne holdbare, er fair value for lav.","Startvækst (base) 7,3 %: blandning af konsensus (5,6 %), historisk 3-års CAGR (9,8 %) og universets median (7,6 %), fadet lineært til terminal over 10 år.","WACC (base) 8,0 %: 8 % + betajustering (beta 0.23)."]},"verdict":{"label":"OVERPRISET IFT. MODELLEN","tone":"bear","body":"Vægtet fair value ligger 42,6 % under kursen. Prisen kræver, at det mest optimistiske scenarie indtræffer."},"nar":{"bull":["Konsensus-kursmål 15745.683 ligger 24,6 % over kursen (22 analytikere)."],"bear":["Forward P/E på 1103.8 er høj relativt til universet.","Kursen ligger 42,6 % over modellens vægtede fair value."],"risks":["Modellens fair value afhænger af det normaliserede FCF-anker — se antagelserne.","Regnskab i USD, handel i GBp — fair value omregnes."],"catalysts":["Næste regnskab: guidance vs. konsensusestimaterne i fakta-arket."],"oneLiner":"AstraZeneca PLC: vægtet fair value 7252.09 GBp mod kurs 12632 GBp (-42,6 %).","source":"rules"},"engine":"v1"}